Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
I'm LongbridgeAI, I can summarize articles.
Kahn Swick & Foti, LLC is investigating the proposed merger between Barinthus Biotherapeutics plc (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Following the merger, Barinthus shareholders will hold only 34.33% of the new entity. The firm aims to assess the fairness and adequacy of the merger process for Barinthus shareholders. Interested parties can contact KSF Managing Partner Lewis S. Kahn for more information regarding their legal rights related to the transaction.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments